Literature DB >> 21814754

Rheumatoid factor and antibodies against citrullinated peptides in Moroccan patients with rheumatoid arthritis: association with disease parameters and quality of life.

Yousra Ibn Yacoub1, Bouchra Amine, Assia Laatiris, Najia Hajjaj-Hassouni.   

Abstract

We aimed to evaluate the immunological status and its relationships with disease-related parameters of activity, severity and quality of life in Moroccan patients with rheumatoid arthritis (RA). Two hundred forty-five consecutive patients with RA were recruited. The following data were collected: demographic characteristics, disease duration (years), disease activity (evaluated by the disease activity score, DAS28), structural damage (evaluated by Sharp's method as modified by van der Heijde), functional disability (assessed by using the Moroccan version of the Health Assessment Questionnaire, HAQ) and quality of life (by using the Arabic version of the Medical Outcomes Study Short Form 36 Health Survey: the SF-36). Immunological status (rheumatoid factor rate, RF) and antibodies against citrullinated peptides rate (ACPAs) by the Elisa method were examined. ACPAs were detected in 75.1% of patients with a mean rate of 79.2 ± 43.8 UI. RF was detected in 80.8% of patients with a mean rate of 80.1 ± 50.6 UI. Patients with positive RF and ACPAs had higher disease activity, impaired functional ability, severe structural damage, more ocular symptoms and altered aspects of quality of life. In univariate analysis, higher levels of ACPAs were significantly correlated with the age at onset (r = 0.307), disease duration (r = 0.520), disease activity (DAS28) (r = 0.531), Sharp score (r = 0.431), and with the deterioration of all domains of SF-36 (for all p ≤ 0.01). RF levels were correlated with disease duration (r = 0.517), disease activity (r = 0.470), functional disability (r = 0.521), and the alteration of physical domains of SF-36 (for all p ≤ 0.01). In multivariate analysis, the main factors associated to ACPAs and RF levels were functional disability, structural damage and impaired QoL. Furthermore, using the SF-36 scores as dependent variables, the impairment of physical domains and the domain of vitality were significantly associated with ACPA levels while the decrease of the domain of physical function was associated with the level of RF. Our study suggests that the presence and the levels of ACPAs and RF in our RA patients are associated with more active disease, more severe joint damage, worst functional disability and altered aspects of quality of life.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21814754     DOI: 10.1007/s10067-011-1820-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  32 in total

1.  Fatigue and severity of rheumatoid arthritis in Moroccan patients.

Authors:  Yousra Ibn Yacoub; Bouchra Amine; Assia Laatiris; Fahd Wafki; Fatima Znat; Najia Hajjaj-Hassouni
Journal:  Rheumatol Int       Date:  2011-03-30       Impact factor: 2.631

2.  Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis.

Authors:  S Bas; S Genevay; O Meyer; C Gabay
Journal:  Rheumatology (Oxford)       Date:  2003-05       Impact factor: 7.580

Review 3.  Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review.

Authors:  J Avouac; L Gossec; M Dougados
Journal:  Ann Rheum Dis       Date:  2006-04-10       Impact factor: 19.103

4.  Correlation of anti-cyclic citrullinated antibody with hand joint erosion score in rheumatoid arthritis patients.

Authors:  Hyun Hee Kim; Jihun Kim; Sung-Hoon Park; Seong-Kyu Kim; Ok-Dong Kim; Jung-Yoon Choe
Journal:  Korean J Intern Med       Date:  2010-06-01       Impact factor: 3.165

5.  Psychometric evaluation of a Moroccan version of health assessment questionnaire for use in Moroccan patients with rheumatoid arthritis.

Authors:  Fatima Ezzahra Abourazzak; Karima Benbouazza; Bouchra Amine; Rachid Bahiri; Noufissa Lazrak; Fatiha Bzami; Imane Jroundi; Redouane Abouqal; Francis Guillemin; Najia Hajjaj-Hassouni
Journal:  Rheumatol Int       Date:  2008-06-06       Impact factor: 2.631

6.  Strong combined gene-environment effects in anti-cyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case-control study in Denmark.

Authors:  Merete Pedersen; Søren Jacobsen; Peter Garred; Hans O Madsen; Mette Klarlund; Arne Svejgaard; Bo V Pedersen; Jan Wohlfahrt; Morten Frisch
Journal:  Arthritis Rheum       Date:  2007-05

7.  Impact of rheumatoid arthritis on quality of life.

Authors:  Nigil Haroon; Amita Aggarwal; Able Lawrence; Vikas Agarwal; Ramnath Misra
Journal:  Mod Rheumatol       Date:  2007-08-20       Impact factor: 3.023

8.  [Sicca syndrome in major collagen diseases].

Authors:  Carmen Mocanu; Flori Bârjovanu; Doina Bărăscu
Journal:  Oftalmologia       Date:  2007

9.  Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis.

Authors:  Annette H M van der Helm-van Mil; Kirsten N Verpoort; Ferdinand C Breedveld; René E M Toes; Tom W J Huizinga
Journal:  Arthritis Res Ther       Date:  2005-06-14       Impact factor: 5.156

10.  Diagnostic performance and predictive value of rheumatoid factor, anti-cyclic-citrullinated peptide antibodies and HLA-DRB1 locus genes in rheumatoid arthritis.

Authors:  Nihal A Fathi; Azza M Ezz-Eldin; Eman Mosad; Rania M Bakry; Hosny B Hamed; Sahar Ahmed; Marwa Mahmoud; Hebat-Allah G Rashed; Fatma Abdullah
Journal:  Int Arch Med       Date:  2008-10-22
View more
  11 in total

1.  MRI assessment of erosion repair in patients with long-standing rheumatoid arthritis receiving double-filtration plasmapheresis in addition to leflunomide and methotrexate: a randomized controlled trial.

Authors:  Xiaoxia Yu; Lei Zhang; Lixin Wang; Weiwei Lu; Fengyan Sun; Ping Xu; Guobin Lan
Journal:  Clin Rheumatol       Date:  2018-01-08       Impact factor: 2.980

2.  Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis.

Authors:  Wanruchada Katchamart; Ajchara Koolvisoot; Emvalee Aromdee; Praveena Chiowchanwesawakit; Chayawee Muengchan
Journal:  Rheumatol Int       Date:  2015-04-23       Impact factor: 2.631

3.  Greek rheumatoid arthritis patients have elevated levels of antibodies against antigens from Proteus mirabilis.

Authors:  Georgios Christopoulos; V Christopoulou; J G Routsias; A Babionitakis; C Antoniadis; G Vaiopoulos
Journal:  Clin Rheumatol       Date:  2016-10-08       Impact factor: 2.980

4.  Analysis of Serum Immune Markers in Seropositive and Seronegative Rheumatoid Arthritis Among Sudanese Patients and the Relation Between the Serotype and Joint Involvement: A Cohort Study.

Authors:  Ahmed Seri; Hala Kamal Ali Mohamed; Mohammed Elmujtba Adam Essa; Elnour Mohammed Elagib; Noha Ibrahim Ahmed Eltahirm; Salma Mohammed Alfatih Mansour; Abdelkareem A Ahmed
Journal:  Open Access Rheumatol       Date:  2021-11-30

5.  Anticyclic citrullinated peptide antibody and rheumatoid factor in south Tunisian patients with rheumatoid arthritis: association with disease activity and severity.

Authors:  Mariem Ben Hamad; Sameh Marzouk; Neila Kaddour; Hatem Masmoudi; Faiza Fakhfakh; Ahmed Rebai; Zouhir Bahloul; Abdellatif Maalej
Journal:  J Clin Lab Anal       Date:  2013-12-27       Impact factor: 2.352

6.  Metabolic syndrome in rheumatoid arthritis: case control study.

Authors:  Samira Rostom; Mariam Mengat; Racha Lahlou; Asmaa Hari; Rachid Bahiri; Najia Hajjaj-Hassouni
Journal:  BMC Musculoskelet Disord       Date:  2013-04-26       Impact factor: 2.362

7.  Autoimmunity in Rheumatic Diseases Is Induced by Microbial Infections via Crossreactivity or Molecular Mimicry.

Authors:  Taha Rashid; Alan Ebringer
Journal:  Autoimmune Dis       Date:  2012-02-20

8.  The influence of polygenic risk scores on heritability of anti-CCP level in RA.

Authors:  J Cui; K E Taylor; Y C Lee; H Källberg; M E Weinblatt; J S Coblyn; L Klareskog; L A Criswell; P K Gregersen; N A Shadick; R M Plenge; E W Karlson
Journal:  Genes Immun       Date:  2014-01-02       Impact factor: 2.676

Review 9.  Goals for rheumatoid arthritis: treating to target or treating to prevent?

Authors:  Min Yang; Mingyang Guo
Journal:  Open Access Rheumatol       Date:  2012-07-09

10.  Anti-Citrullinated Cyclic Peptide Antibody and Functional Disability Are Associated With Poor Sleep Quality in Rheumatoid Arthritis.

Authors:  Shamala Rajalingam; Rajalingham Sakthiswary; Heselynn Hussein
Journal:  Arch Rheumatol       Date:  2016-12-08       Impact factor: 1.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.